How aspirin works
August 1, 1995
New understanding of an old remedy may spell relief for millions who take non-steroidal anti-inflammatory drugs
Aspirin is nearly a hundred years old, and its forerunner, willow bark, was used since the dawn of history. Only recently did scientists discover the target of these drugs, and now researchers at the University of Chicago Medical Center have revealed the precise chemical mechanism of how aspirin stops pain and inflammation. The finding, reported in the journal Nature/Structural Biology, means that millions of arthritis sufferers and others who regularly take aspirin to reduce pain and inflammation may be able to look forward to improved drugs with fewer side effects.
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and indomethacin work by inhibiting an enzyme that produces prostaglandins--hormone-like messenger molecules that trigger many processes in the body, including inflammation. The Chicago researchers have shown that aspirin splits into two parts and affixes one part to the enzyme, permanently altering its chemical structure and blocking the reaction that produces prostaglandins. Aspirin is the only NSAID known to work in this manner.
The new finding follows a report last year from this same research team, led by Michael Garavito, associate professor of biochemistry and molecular biology, in which they determined the molecular structure of the enzyme, prostaglandin H2 synthase, or PGHS. Using X-rays to probe the positions of atoms in tiny crystals of the enzyme, they showed that PGHS has a tunnel running into the middle of it. The raw material must pass through this tunnel to reach the core of the enzyme, where it will be converted into prostaglandin.
Today the team reports that aspirin permanently attaches a portion of itself inside the tunnel, where it acts like a gate, blocking prostaglandin's precursor from reaching the "active site" of the enzyme. They further showed that this gate can be in two positions, either fully or partially closed, and that the position of the gate may differ between two forms of the enzyme found in the body. Finding such differences between the two forms is the key to developing improved NSAIDs.
Four years ago several groups found that the body has two types of prostaglandin H2 synthase: an ever-ready PGHS-1, present in nearly all cells for basic housekeeping duties, and PGHS-2, made only as needed and just by those cells involved in inflammation and immune responses. Unfortunately for pain sufferers--and especially for rheumatoid arthritis patients, who must take huge doses daily--none of the current crop of 16 NSAIDs discriminates between the two enzyme forms. Before it can trickle into the bloodstream and alleviate inflammation by reining in PGHS-2, the drug lands with a thud in the stomach, where it knocks out PGHS-1, causing excess acid secretion and stomach upset or ulcers.
"Just four years ago the consensus in the pharmaceutical community was you couldn't build a better aspirin," says Garavito. "But understanding the differences between the two forms of PGHS may allow us to do exactly that. We know that PGHS-2 is only partly blocked by aspirin, while PGHS-1 is completely knocked out. This paper shows why this might be so. The bottom line is that although the two forms of the enzyme seem very similar, their active sites are subtly different, and this could be a basis for rational drug design."
Garavito and research associates Daniel Picot and Patrick Loll (Picot is now at the Institut de Biologie Physico-Chimique in Paris) grew crystals of PGHS-1 using a technique that took them six years to develop. They diffused into the growing crystals an analog of aspirin that contains a bromine atom to aid in the X-ray crystallography.
PGHS-1 is tightly bound to an intracellular membrane. Such proteins are notoriously difficult to study because the detergents needed to separate the protein from the greasy membrane make crystallization difficult. The researchers use PGHS-1 isolated from sheep seminal vesicles. By slowly changing the composition of the solution and the surrounding vapor over a period of weeks, the researchers were able to grow brown, rod shaped crystals almost one sixteenth of an inch long for study.
Drug developers are most interested in targeting PGHS-2, and Garavito's laboratory is trying to grow crystals of that form of the enzyme large enough to X-ray. But aspirin's beneficial effects in preventing vascular disease and heart attacks are thought to be a PGHS-1 phenomenon, and improved anti-platelet drugs may derive directly from today's study, which was funded by the National Institutes of Health.
The University of Chicago Medicine
950 E. 61st Street, Third Floor
Chicago, IL 60637
Phone (773) 702-0025 Fax (773) 702-3171